FDA Approval For Travere's Drug Expands Reach To Broader Rare Kidney Disease PatientsBenzinga • 04/14/26
Travere Therapeutics, Inc. (TVTX) Discusses FDA Approval of FILSPARI as First Approved Medicine for FSGS TranscriptSeeking Alpha • 04/14/26
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGSBusiness Wire • 04/13/26
Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsBusiness Wire • 02/19/26
Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial ResultsBusiness Wire • 02/12/26
Travere Therapeutics (TVTX) Earnings Expected to Grow: Should You Buy?Zacks Investment Research • 02/12/26
Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech SummitBusiness Wire • 02/04/26
TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Encourages Investors and Potential Witnesses to Contact Law FirmGlobeNewsWire • 01/31/26
Travere Therapeutics: Filspari's FSGS Approval Chance Is Higher Than You ThinkSeeking Alpha • 01/29/26
TVTX INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law FirmPRNewsWire • 01/28/26
TVTX: Travere Therapeutics Shareholders Should Contact Block & Leviton To Potentially Recover LossesGlobeNewsWire • 01/27/26
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy?The Motley Fool • 01/25/26
Travere Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow TVTX Investors to Recover LossesNewsfile Corp • 01/16/26
TVTX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law FirmBusiness Wire • 01/16/26
INVESTOR ALERT: Investigation of Travere Therapeutics, Inc. (TVTX) by Holzer & Holzer, LLCGlobeNewsWire • 01/14/26
TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDAZacks Investment Research • 01/14/26